Cited by 13Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisAtomic and Subatomic Physics ResearchAdvanced MRI Techniques and Applications

Imaging biomarkers of lung ventilation in interstitial lung disease from 129Xe and oxygen enhanced 1H MRI

Open access
Tibiletti, Marta, Eaden, James A., Naish, Josephine H., Hughes, Paul J.C., Waterton, John C., Heaton, Matthew J., Chaudhuri, Nazia, Skeoch, Sarah +4 more·2023·Magnetic Resonance Imaging

Abstract

To compare imaging biomarkers from hyperpolarised 129Xe ventilation MRI and dynamic oxygen-enhanced MRI (OE-MRI) with standard pulmonary function tests (PFT) in interstitial lung disease (ILD) patients. To evaluate if biomarkers can separate ILD subtypes and detect early signs of disease resolution or progression. Prospective longitudinal. Forty-one ILD (fourteen idiopathic pulmonary fibrosis (IPF), eleven hypersensitivity pneumonitis (HP), eleven drug-induced ILD (DI-ILD), five connective tissue disease related-ILD (CTD-ILD)) patients and ten healthy volunteers imaged at visit 1. Thirty-four ILD patients completed visit 2 (eleven IPF, eight HP, ten DIILD, five CTD-ILD) after 6 or 26 weeks. MRI was performed at 1.5 T, including inversion recovery T1 mapping, dynamic MRI acquisition with varying oxygen levels, and hyperpolarised 129Xe ventilation MRI. Subjects underwent standard spirometry and gas transfer testing. Five 1H MRI and two 129Xe MRI ventilation metrics were compared with spirometry and gas transfer measurements. To evaluate differences at visit 1 among subgroups: ANOVA or Kruskal-Wallis rank tests with correction for multiple comparisons. To assess the relationships between imaging biomarkers, PFT, age and gender, at visit 1 and for the change between visit 1 and 2: Pearson correlations and multilinear regression models. The global PFT tests could not distinguish ILD subtypes. Percentage ventilated volumes were lower in ILD patients than in HVs when measured with 129Xe MRI (HV 97.4 ± 2.6, CTD-ILD: 91.0 ± 4.8 p = 0.017, DI-ILD 90.1 ± 7.4 p = 0.003, HP 92.6 ± 4.0 p = 0.013, IPF 88.1 ± 6.5 p < 0.001), but not with OE-MRI. 129Xe reported more heterogeneous ventilation in DI-ILD and IPF than in HV, and OE-MRI reported more heterogeneous ventilation in DI-ILD and IPF than in HP or CTD-ILD. The longitudinal changes reported by the imaging biomarkers did not correlate with the PFT changes between visits. Neither 129Xe ventilation nor OE-MRI biomarkers investigated in this study were able to differentiate between ILD subtypes, suggesting that ventilation-only biomarkers are not indicated for this task. Limited but progressive loss of ventilated volume as measured by 129Xe-MRI may be present as the biomarker of focal disease progresses. OE-MRI biomarkers are feasible in ILD patients and do not correlate strongly with PFT. Both OE-MRI and 129Xe MRI revealed more spatially heterogeneous ventilation in DI-ILD and IPF.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.mri.2022.10.005

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In another study, ventilation or oxygen enhanced-MRI biomarkers were not able to discriminate between different types of interstitial lung disease.

    “However, in another study, ventilation or oxygen enhanced-MRI biomarkers were not able to discriminate between the different types of interstitial lung disease (ILD) (Tibiletti et al., 2023).”

    From Pulmonary fibrosis: Emerging diagnostic and therapeutic strategies (2023) · cites this paper as Tibiletti et al., 2023

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 47 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

  1. Stewart NJ, Chan H, Hughes PJC, Horn FC, Norquay G, Rao M, et al. Comparison of 3He and 129Xe MRI for evaluation of lung microstructure and ventilation at 1.5 T. J Magn Reson Imaging 2018;48:632-42.

Cited by

Sorted by citations

Authors
Tibiletti, M., Eaden, J. A., Naish, J. H., Hughes, P. J. C., Waterton, J. C., Heaton, M. J., Chaudhuri, N., Skeoch, S., Bruce, I. N., Bianchi, S., Wild, J. M., & Parker, G. J. M.
Affiliations
  • University of Sheffield (GB)
  • Manchester University NHS Foundation Trust (GB)
  • University of Manchester (GB)
  • Manchester Academic Health Science Centre (GB)
  • Royal National Hospital for Rheumatic Diseases (GB)
  • Sheffield Teaching Hospitals NHS Foundation Trust (GB)
  • Insigneo (GB)
  • University College London (GB)
Corresponding author
Parker, Geoff J.M.
Venue
Magnetic Resonance Imaging
Publisher
Elsevier BV
Published
2023-01
Volume
95
Pages
39-49
ISSN
0730-725X (ISSN-L)
OpenAlex
W4306319281
Cited by
13
References
47
Citations by year
2026: 3 · 2025: 5 · 2024: 1 · 2023: 4
FWCI
1.61
Type
journal article
Language
en
Open access
Locations
  • Magnetic Resonance Imaging (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
  • UCL Discovery (University College London) (submittedVersion, cc-by)
  • Ulster University Research Portal (Ulster University) (submittedVersion, cc-by)
Funders
  • Innovative Medicines Initiative (116106)
  • NIH
  • GlaxoSmithKline (BIDS3000032592)
  • Medical Research Council (MR/M008894/1)
  • National Institute for Health and Care Research
  • Department of Health and Social Care
  • European Federation of Pharmaceutical Industries and Associations
  • European Commission
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Physical Sciences › Physics and Astronomy › Atomic and Molecular Physics, and Optics › Atomic and Subatomic Physics Research
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Advanced MRI Techniques and Applications
Keywords
interstitial lung disease, pulmonary ventilation, imaging biomarkers, oxygen-enhanced MRI, idiopathic pulmonary fibrosis, hypersensitivity pneumonitis, drug-induced interstitial lung disease, connective tissue disease-associated interstitial lung disease, pulmonary function tests, gas transfer, ventilation heterogeneity, disease progression, disease resolution, ILD subtypes
MeSH terms
Humans, Lung, Magnetic Resonance Imaging, Oxygen, Prospective Studies, Biomarkers, Lung Diseases, Interstitial, Idiopathic Pulmonary Fibrosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review